Diplomat Pharmacy (NYSE:DPLO) spotted trading -77.23% off 52-week high price. On the other end, the stock has been noted 17.27% away from the low price over the last 52-weeks. The stock changed -1.01% to recent value of $4.89. The stock transacted 515244 shares during most recent day however it has an average volume of 755.28K shares. The company has 76.61M of outstanding shares and 57.6M shares were floated in the market.
On Oct. 2, 2019, Diplomat Pharmacy (NYSE:DPLO) has appointed David Skomo as chief operating officer of CastiaRx following the retirement of Chris Luthin. CastiaRx, a division of Diplomat, is a pharmacy benefit manager (PBM) that helps healthcare payers manage specialty pharmacy costs.
Previously, Luthin and Skomo worked closely to develop differentiated solutions for payers for their pharmacy and specialty benefit challenges. CastiaRx remains committed to investing in people, processes, technology, and infrastructure to add value for clients and plan members.
Skomo joined CastiaRx in 2018 as a member of the leadership team, most recently serving as the senior vice president of PBM operations. During the past 14 months, Skomo has applied his considerable skills and industry knowledge to transform key operational areas of the company, notably mail-order prescription fulfillment and contact-center operations.
Dave has been instrumental in transforming our mail-order business and contact-center operations to meet and exceed industry standards, Diplomat CEO Brian Griffin said. His impressive background of leading process improvement and offering guidance to enable technology-based solutions has already been a great asset to CastiaRx.
Its earnings per share (EPS) expected to touch remained -470.80% for this year while earning per share for the next 5-years is expected to reach at -5.44%. DPLO has a gross margin of 6.40% and an operating margin of -8.30% while its profit margin remained -8.90% for the last 12 months.
According to the most recent quarter its current ratio was 1 that represents company’s ability to meet its current financial obligations. The price moved ahead of -11.58% from the mean of 20 days, -11.32% from mean of 50 days SMA and performed -32.90% from mean of 200 days price. Company’s performance for the week was -3.17%, -21.76% for month and YTD performance remained -63.67%.